Non-Aspergillus invasive mold infections in patients treated with ibrutinib.
Mycoses. 2020 May 27;:
Authors: Anastasopoulou A, DiPippo AJ, Kontoyiannis DP
BACKGROUND: Invasive mold infections (IMIs) are very rare in patients with lymphoid malignancies. However, IMIs, mostly due to Aspergillus species, have been increasingly reported in such patients receiving ibrutinib (IBR). There is paucity of information regarding non-Aspergillus invasive mold infections (NAIMIs) in this setting, OBJECTIVES: To review our experience the published literature on the topic.
PATIENTS/METHODS: We present a case of invasive sinusitis caused by Fusarium in a patient with refractory chronic lymphocytic leukemia (CLL) who was treated with IBR and review the 12 published cases of NAIMIs during IBR.
RESULTS: Nearly all cases of NAIMIs in the setting of IBR use were encountered in patients with CLL. Mixed fungal infections, brain involvement as well as late-onset infections were common.
CONCLUSIONS: Although rare, NAIMIs should be considered in patients who receive IBR.
PMID: 32458510 [PubMed – as supplied by publisher]